Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.30
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsPremera Peginterferon Coverage Update | OpenPayer
    Ask Trek AI about this page
    ModifiedPremera Blue Cross of WashingtonPolicy 5.01.664

    Peginterferon alfa-2a

    Customize your policy alerts

    Sign up for premerabluecrossofwashington Policy 5.01.664 alerts

    Get alerted when Policy 5.01.664 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs pharmacy-benefit coverage of Pegasys (peginterferon alfa-2a) for specified chronic viral infections, essential thrombocytopenia, and myelofibrosis. Coverage depends on meeting condition-specific medical necessity criteria and submitting supporting clinical documentation.

    Policy Summary
    PayerPremera Blue Cross of Washington
    PolicyPeginterferon alfa-2a
    Policy CodePolicy 5.01.664
    Change TypeNew policycriteria consolidated
    Effective DateNovember 1, 2026
    Next Review DateNot specified
    Key ActionSubmit medical records documenting that the applicable medical necessity criteria are met, including diagnosis, relevant history, physical evaluation, laboratory tests, and medication history.
    SourceLink
    POLICY UPDATE CHANGES

    A new policy, 5.01.664 Peginterferon alfa-2a, was approved on October 13, 2026, with an effective date of November 1, 2026.

    Coverage criteria for Pegasys were moved from policy 5.01.636 Chronic Hepatitis B and D Antiviral Therapy to this policy.

    Coverage criteria for Pegasys were moved from policy 5.01.606 Hepatitis C Antiviral Therapy to this policy.

    12 monthsMaximum initial approval
    12 monthsMaximum reauthorization
    48 weeks

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Covered hepatitis D treatment
    3 yearsMinimum pediatric age
    180 mcg weeklyPegasys dosing in studies

    Medical Necessity and Coverage Scope

    Medically Necessary Indications

    Pegasys (peginterferon alfa-2a) may be considered medically necessary when used for any of the following indications and criteria:

    ONE of the following indications

    • Chronic hepatitis B virus infection — adults

      • Individual is aged 18 years or older with HBeAg-positive or HBeAg-negative chronic HBV infection.
      • Individual has compensated liver disease.
      • There is evidence of viral replication and liver inflammation.

    • Chronic hepatitis B virus infection — pediatric individuals

      • Individual is aged 3 years or older and is non-cirrhotic.
      • Individual has HBeAg-positive chronic hepatitis B (CHB).
      • There is evidence of viral replication and elevations in serum alanine aminotransferase (ALT).
    • Treatment of chronic hepatitis C virus infection when used in accordance with current guidelines.

    • Chronic hepatitis D virus infection

      • Individual has compensated liver disease.
      • Pegasys (peginterferon alfa-2a) is used as a single agent for 48 weeks.
    • First- or second-line treatment of an individual with essential thrombocytopenia.

    • Myelofibrosis

      • Individual is aged 18 years or older.
      • Individual has myelofibrosis with a JAK2 V617F mutation.

    Unlisted Indications

    Uses of Pegasys (peginterferon alfa-2a) for conditions not outlined in this policy are considered investigational and are not medically necessary under this policy.

    Any indication or use of Pegasys other than the covered indications and applicable criteria listed in this policy is considered investigational.

    COVERAGE CRITERIA: All other uses of Pegasys (peginterferon alfa-2a) for conditions not outlined in this policy are considered investigational.

    Authorization and Documentation Requirements

    Prior Authorization

    Document medical necessity for initial authorization

    Coverage requires documentation that the individual meets the applicable, condition-specific medical necessity criteria for Pegasys. Initial authorization may be approved for up to 12 months.

    Prior Authorization

    Support reauthorization with continued response

    Reauthorization may be granted for up to 12 months when the medical necessity criteria continue to be met and the individual has a positive clinical response to Pegasys therapy, supported by submitted medical records.

    Documentation Required

    Submit required clinical records

    Peginterferon Alfa-2a Overview

    Peginterferon alfa-2a is an alpha interferon that helps regulate immune responses and may inhibit viral replication and abnormal cell growth. The policy addresses its use in chronic hepatitis B, chronic hepatitis C, chronic hepatitis D, essential thrombocytopenia, and myelofibrosis with a JAK2 V617F mutation. Pegasys is managed through the pharmacy benefit.

    Clinical Definitions

    Hepatitis B surface antigen (HBsAg)
    LocationFound on the surface of the hepatitis B virus.
    InfectiousnessAll persons with HBsAg are infectious.
    Clinical implicationDetection of HBsAg indicates the person is infectious.
    Hepatitis B e-antigen (HBeAg)
    LocationFound in the inner core of the hepatitis B virus.
    InfectiousnessPersons with positive HBeAg are described as most infectious.
    Clinical implicationA positive HBeAg result indicates a high level of infectiousness.

    Initial Therapy

    Reauthorization and Continued Therapy

    Policy Summary
    PayerPremera Blue Cross of Washington
    PolicyPeginterferon alfa-2a
    Policy CodePolicy 5.01.664
    Change TypeNew policycriteria consolidated
    Effective DateNovember 1, 2026
    Next Review DateNot specified
    Key ActionSubmit medical records documenting that the applicable medical necessity criteria are met, including diagnosis, relevant history, physical evaluation, laboratory tests, and medication history.
    SourceLink
    On This Page
    Medical Necessity and Coverage ScopeAuthorization and Documentation RequirementsPeginterferon Alfa-2a OverviewClinical DefinitionsInitial TherapyReauthorization and Continued Therapy

    Submit medical records documenting that the applicable medical necessity criteria are met. Include office visit notes containing the diagnosis, relevant history, physical evaluation, laboratory tests, and medication history.

    Denial Risk

    Avoid unlisted indications

    Use of Pegasys for a condition or indication not outlined in the policy is considered investigational and is not covered as medically necessary under this policy.

    Denial Risk

    Demonstrate positive response for renewal

    Reauthorization requires that the medical necessity criteria remain met and that the individual continues to demonstrate a positive clinical response to therapy. Without evidence of continued positive response, reauthorization requirements are not met.

    HBV DNA
    Molecular definitionA partially double-stranded DNA molecule.
    LocationFound in the inner core of the hepatitis B virus.
    Infectivity relationshipElevated HBV DNA is associated with higher infectivity.
    Chronic hepatitis B (CHB)
    Diagnostic durationHBsAg positive for at least 6 months.
    Viral and biochemical findingsHBV DNA may range from undetectable to several billion IU/mL, and ALT and/or AST levels may be normal or elevated.
    Liver findingsLiver biopsy results show chronic hepatitis with variable necroinflammation and/or fibrosis.
    Immune-active CHB
    HBeAg-positive thresholdHBV DNA levels greater than 20,000 IU/mL in HBeAg-positive CHB.
    HBeAg-negative thresholdHBV DNA levels greater than 2,000 IU/mL in HBeAg-negative CHB.
    Disease activityALT and/or AST levels are intermittently or persistently elevated, with moderate or severe hepatic necroinflammation and with or without fibrosis.
    HBeAg seroconversion
    HBeAg statusLoss of HBeAg.
    Anti-HBe statusDetection of anti-HBe.
    Prior statusOccurs in a person who was previously HBeAg positive and anti-HBe negative.
    Early virologic response (EVR)
    Response measureClearance of HCV RNA.
    Assessment periodDuring the first 12 weeks of therapy.
    Partial response distinctionA partial response is a minimum 2-log decrease in hepatitis C viral load after 12 weeks of therapy.
    Sustained virologic response (SVR)
    Response measureClearance of HCV RNA by qualitative analysis.
    Assessment timingTwenty-four weeks after therapy cessation.
    DefinitionAn SVR is clearance of HCV RNA 24 weeks after therapy cessation.
    Sustained virologic response (SVR)
    DefinitionClearance of HCV RNA by qualitative analysis 24 weeks after therapy cessation.
    Response benchmarkThe current gold-standard measure of response to chronic HCV pharmacotherapy.
    Clinical significanceAchievement of an SVR has been associated with resolution of liver injury, reduction in hepatic fibrosis, a low likelihood of relapse, and survival.
    Early virologic response (EVR)
    Viral markerHCV RNA.
    Response definitionClearance of HCV RNA.
    Assessment periodDuring the first 12 weeks of therapy.
    Partial response
    Response measureDecrease in hepatitis C viral load.
    Minimum decreaseAt least 2 log.
    Assessment timingAfter 12 weeks of therapy.
    Relapse
    Initial responseInitial achievement of a sustained virologic response.
    Loss of responseThe sustained virologic response is not maintained.
    Time courseThe response is not sustained over time.
    Nonresponse
    Response statusNever achieving a sustained virologic response.
    SVR statusNo SVR is achieved at any point.
    Distinction from relapseUnlike relapse, nonresponse does not involve an initial achievement of SVR.